Below are the top 10 Biotech stocks with highest upside potential, based on the
difference between current price and Wall Street analysts average target price.
One Chinese company (CPHI) is on the list. Bionovo Inc. (NASDAQ:BNVI) has the
1st highest upside potential in this segment of the market. Its upside is
941.7%. Its consensus target price is $5.00 based on the average of all
estimates. Palatin Technologies, Inc. (AMEX:PTN) has the 2nd highest upside
potential in this segment of the market. Its upside is 880.4%. Its consensus
target price is $5.00 based on the average of all estimates. Peregrine
Pharmaceuticals (NASDAQ:PPHM) has the 3rd highest upside potential in this
segment of the market. Its upside is 612.6%. Its consensus target price is $7.13
based on the average of all estimates. Galena Biopharma Inc (NASDAQ:GALE) has
the 4th highest upside potential in this segment of the market. Its upside is
525.0%. Its consensus target price is $4.50 based on the average of all
estimates. CEL-SCI Corporation (AMEX:CVM) has the 5th highest upside potential
in this segment of the market. Its upside is 471.4%. Its consensus target price
is $2.00 based on the average of all estimates. Neostem Inc. (AMEX:NBS) has the
6th highest upside potential in this segment of the market. Its upside is
465.1%. Its consensus target price is $3.56 based on the average of all
estimates. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has the 7th highest
upside potential in this segment of the market. Its upside is 444.4%. Its
consensus target price is $6.75 based on the average of all estimates. Tengion,
Inc. (NASDAQ:TNGN) has the 8th highest upside potential in this segment of the
market. Its upside is 414.7%. Its consensus target price is $2.65 based on the
average of all estimates. China Pharma Holdings, Inc. (AMEX:CPHI) has the 9th
highest upside potential in this segment of the market. Its upside is 405.6%.
Its consensus target price is $4.50 based on the average of all estimates. iBio,
Inc. (AMEX:IBIO) has the 10th highest upside potential in this segment of the
market. Its upside is 370.6%. Its consensus target price is $8.00 based on the
average of all estimates.
No comments:
Post a Comment